FDA_Warning_Letters, Import_Alerts_&_EU_Non-Compliances_in_2019
X

Find Clinical Drug Pipelines for Trauma (Emergency, Injury, Surgery)

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Study Phase filter
    Country filter
      News Type filter
        Company filter
          Product Type filter
            refresh

            Product Type

            Development Status

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Autologous regenerative epidermal cells

            Therapeutic Area: Trauma (Emergency, Injury, Surgery)

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 04, 2020

            Details:

            This study seeks to demonstrate that treatment with the RECELL System of partial-thickness burn injuries within 72-hours can safely increase the healing at day 10.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PLX-R18

            Therapeutic Area: Trauma (Emergency, Injury, Surgery)

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 03, 2020

            Details:

            The decision is based on BARDA’s technical considerations as determined by a Technical Evaluation Panel. Other factors included BARDA’s current strategic needs, availability of funds and resources.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Dialkylcarbamoylchloride

            Therapeutic Area: Trauma (Emergency, Injury, Surgery)

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Essity

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition February 27, 2020

            Details:

            ABIGO Medical has leading innovations in advanced wound care that reduce the spread of bacteria without increasing resistance to antibiotics.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Dexamethasone

            Therapeutic Area: Trauma (Emergency, Injury, Surgery)

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Guggenheim Securities

            Deal Size: $21.7 million Upfront Cash: Undisclosed

            Deal Type: Public Offering February 20, 2020

            Details:

            EyePoint intends to use the net proceeds of the offering to continue to fund the commercialization and expand the access of DEXYCU® and YUTIQ® and for general corporate purposes.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Dexamethasone

            Therapeutic Area: Trauma (Emergency, Injury, Surgery)

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Vision Center Network of America

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement February 18, 2020

            Details:

            The agreement will enable VCNA physicians to incorporate DEXYCU into their surgical protocols for treating ocular inflammation associated with cataract surgery.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Dexamethasone

            Therapeutic Area: Trauma (Emergency, Injury, Surgery)

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Ocumension Therapeutics

            Deal Size: $14.0 million Upfront Cash: $2.0 million

            Deal Type: Licensing Agreement February 03, 2020

            Details:

            Ocumension will receive exclusive rights to develop and commercialize the product in Mainland China, Hong Kong, Macau and Taiwan.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ronopterin

            Therapeutic Area: Trauma (Emergency, Injury, Surgery)

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 29, 2020

            Details:

            NOSTRA III is a 220 patient Phase III clinical trial assessing efficacy and safety of Ronopternin (VAS203) for the treatment of moderately to severely injured closed head traumatic brain injuries.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PRV-002

            Therapeutic Area: Trauma (Emergency, Injury, Surgery)

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 29, 2020

            Details:

            Prevacus, has completed GMP certification of API for their lead compound for treating concussion and is now preparing the final nano-formulation for nasal application to initiate its first human trials.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Nangibotide

            Therapeutic Area: Trauma (Emergency, Injury, Surgery)

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Roche Diagnostics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement January 21, 2020

            Details:

            Inotrem entered a worldwide licensing agreement with Roche Diagnostics for the commercialization of a mechanism-based companion diagnostic test using a soluble plasma protein.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PB2452

            Therapeutic Area: Trauma (Emergency, Injury, Surgery)

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: SFJ Pharmaceuticals

            Deal Size: $120.0 million Upfront Cash: Undisclosed

            Deal Type: Collaboration January 10, 2020

            Details:

            The collaboration with SFJ provides PhaseBio with substantial funding to continue the rapid advancement of lead program, PB2452.

            PharmaCompass